MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer
Byoung Chul Cho, Chaiyut Charoentum, Dong‐Wan Kim, Cheng‐Ta Yang et autres
2 citationsLung Cancer
Helen Mann
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
243Publications signalées
12006Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Research StudiesNeuroendocrine Tumor Research AdvancesPeptidase Inhibition and AnalysisLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Publications récentes
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, James Chih‐Hsin Yang et autres
99 citationsNew England Journal of Medicine
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
Manuel Cobo, Martin Reck, David H. Harpole, T. Mitsudomi et autres
0 citationsJournal of Thoracic Oncology
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 ADRIATIC Trial
Yoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, Koichi Azuma et autres
1 citationCancer Science
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Niels Reinmuth, Jonathan W. Goldman, Yuanbin Chen, Katsuyuki Hotta et autres
4 citationsClinical Lung Cancer
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study
Mustafa Özgüroğlu, Jonathan W. Goldman, Yuanbin Chen, Marina Chiara Garassino et autres
0 citationsFuture Oncology
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
Solange Peters, Kelly S. Oliner, Anne L’Hernault, M. Ratcliffe et autres
5 citationsESMO Open
188O: Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)
Giulia Pasello, Martin Reck, David H. Harpole, T. Mitsudomi et autres
4 citationsJournal of Thoracic Oncology
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Yu Qian et autres
1 citationNature
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study
Shun Lü, Lin Wu, Qiming Wang, Ziping Wang et autres
10 citationsJournal of Thoracic Oncology
Supplementary Figure S7 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth et autres
0 citations
Supplementary Figure S8 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.